Erenumab
Indications
Erenumab is used for:
Migraine Prophylaxis
Adult Dose
Migraine Prophylaxis
Indicated for preventive treatment of migraines
70 mg SC once monthly
Some patients may need 140 mg SC once monthly (administered as 2 consecutive 70-mg SC doses)
Child Dose
Renal Dose
Renal impairment
Mild-to-moderate: Clinical studies did not reveal a difference in pharmacokinetics
Severe (eGFR <30 mL/min/1.73 m²): Not studied
Administration
Contra Indications
Hypersensitivity to drug or excipients
Precautions
Hypersensitivity reactions (eg, rash, angioedema, anaphylaxis) reported; may occur within hours or one week following administration; discontinue administration and initiate appropriate therapy if serious reaction occurs
Pregnancy-Lactation
Pregnancy
Data are not available regarding fetal risk if used in pregnant women
Animal studies
No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation
Clinical considerations
Data suggest that women with migraine may be at increased risk of preeclampsia during pregnancy
Lactation
Data are not available on the presence in human milk, the effects on the breastfed infant, or the effects on milk production
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Adverse Effects
Side effects of Erenumab :
1-10%
Injection site pain (5-6%)
Constipation (1-3%)
Cramps, muscle spasms (<3%)
Mechanism of Action
Human monoclonal antibody; binds to the calcitonin gene-related peptide (CGRP) receptor, which is thought to be causally involved in migraine pathophysiology